Aurora Nutrascience Inc. – Trademark Portfolio
Entity Type: 03
Aurora Nutrascience Inc. holds 51 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 49 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 22 trademarks are registered and 9 are pending. Notable registered marks include KREO, C-BUSTER, EXOFLEX+, MEGA-PACK+, and MICRO-PACK+. The owner is based in Concord, Ontario.
86 Moyal Ct.
Concord, Ontario L4K4R8 , CA
Showing of trademarks Trademarks
Trademark Classifications
Aurora Nutrascience Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Aurora Nutrascience Inc. have?
Aurora Nutrascience Inc. has 51 U.S. trademarks filed with the USPTO. Of these, 22 registered, 9 pending, 20 abandoned.
What trademark classes does Aurora Nutrascience Inc. file in?
Aurora Nutrascience Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Aurora Nutrascience Inc.'s most well-known trademarks?
Aurora Nutrascience Inc.'s registered trademark portfolio includes well-known marks such as KREO, C-BUSTER, EXOFLEX+, MEGA-PACK+, and MICRO-PACK+. These are among 22 currently registered trademarks in the portfolio.
What is Aurora Nutrascience Inc.'s trademark registration success rate?
Aurora Nutrascience Inc. has a 52% trademark registration rate, with 22 out of 42 resolved applications resulting in successful registration. Currently, 9 applications are pending review.